1
|
Hage L, O’Donnell MA, Abou Chakra M, Kime A, Sibony M, Peyromaure M, Duquesne I. Inflammatory myofibroblastic tumor of the urinary bladder: A systematic review of the literature and report of a case. Indian J Urol 2024; 40:88-95. [PMID: 38725889 PMCID: PMC11078447 DOI: 10.4103/iju.iju_50_24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 03/07/2024] [Accepted: 03/08/2024] [Indexed: 05/12/2024] Open
Abstract
Introduction Inflammatory myofibroblastic tumors (IMTs) are intermediate-grade lesions that frequently recur and rarely metastasize. There are currently no guidelines on the management of bladder IMTs. This systematic review aims to describe the clinical presentation and compare the management options for bladder IMTs. Methods A PubMed/Medline search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, using the following Mesh terms: ("inflammatory myofibroblastic") AND ("tumor") OR ("tumor") AND ("bladder") AND ("case report"). A total of 75 case reports were included in the analysis. Results The mean age of the patients was 36 years. 65% of the cases initially presented with hematuria. 68% of the tumors stained positive for anaplastic lymphoma kinase, and 20% invaded the muscularis. Patients underwent either transurethral resection of the bladder tumor (TURBT) only (34%), TURBT followed by complementary partial cystectomy (16%), or TURBT followed by radical cystectomy (4%). 36% and 9% of the cases underwent partial and radical cystectomy after the initial diagnosis, respectively. Cystectomies were performed using an open (74%), laparoscopic (14%), robotic-assisted (10%), or unknown (2%) approach. At a mean follow-up of 14 months, the recurrence and metastasis rates were about 9% and 4%, respectively. In addition, we present the case of a 49-year-old woman with a bladder IMT who underwent TURBT followed by laparoscopic partial cystectomy. The patient remains tumor free postoperatively (follow-up period of 12 months). Conclusion A complete surgical excision of the bladder IMT is crucial for the optimal management of these cases. Proper differentiation of this tumor from sarcoma or leiomyosarcoma leads to the best outcomes.
Collapse
Affiliation(s)
- Lory Hage
- Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Universite Paris Cite, Paris, France
| | - Michael A O’Donnell
- Department of Urology, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Mohamad Abou Chakra
- Department of Urology, The University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Amel Kime
- Department of Pathology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Universite Paris Cite, Paris, France
| | - Mathilde Sibony
- Department of Pathology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Universite Paris Cite, Paris, France
| | - Michaël Peyromaure
- Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Universite Paris Cite, Paris, France
| | - Igor Duquesne
- Department of Urology, Cochin Hospital, Assistance Publique-Hopitaux de Paris, Universite Paris Cite, Paris, France
| |
Collapse
|
2
|
Chen C, Huang M, He H, Wu S, Liu M, He J, Zang H, Xu R. Inflammatory Myofibroblastic Tumor of the Urinary Bladder: An 11-Year Retrospective Study From a Single Center. Front Med (Lausanne) 2022; 9:831952. [PMID: 35308527 PMCID: PMC8928161 DOI: 10.3389/fmed.2022.831952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Accepted: 02/07/2022] [Indexed: 11/24/2022] Open
Abstract
Purpose To share our experience in the diagnosis and treatment of an inflammatory myofibroblastic tumor of the urinary bladder (IMTUB). Materials and Methods A database searches in the pathology archives by using the term “inflammatory myofibroblastic tumor” and” bladder” in our hospital department of pathology from 2010 to 2021. Patient characteristics, clinical features, histopathological results, immunohistochemical staining results, and treatment outcomes were reviewed. Results Fourteen cases of IMTUB were retrieved. The mean age was 44.7 ± 18.9 years (range 12–74). Nine (64.3%) of the patients presented with hematuria, followed by seven (50%) with odynuria, five (35.7%) with urgent urination, and one (7.1%) with dysuria. Ten (71.4%) of the patients were treated with partial cystectomy (PC), three (21.4%) with transurethral resection of bladder tumor (TURBT), and one (7.1%) with radical cystectomy (RC). Histopathologically, eight (57.1%) had a compact spindle cell pattern. Anaplastic lymphoma kinase (ALK) staining was positive in six (75%) of 8 cases. During a mean follow-up period of 43.9 ± 38 months (range 3–117), a patient had recurrence within half a month. Then, the patient was treated with further TURBT surgery and had no recurrence within 6 months. Thirteen of the patients had no local recurrence or distant metastasis. Conclusion Inflammatory myofibroblastic tumor of the urinary bladder (IMTUB) is clinically rare and has a good prognosis. The disease is mainly treated with surgery to remove the tumor completely. It can easily be misdiagnosed as bladder urothelial carcinoma, leiomyosarcoma, or rhabdomyosarcoma, which may result in overtreatment and poor quality of life of patients.
Collapse
Affiliation(s)
- Can Chen
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Mengjun Huang
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Haiqing He
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Shuiqing Wu
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Mingke Liu
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Jun He
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Hongjing Zang
- Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Ran Xu
- Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, China
- *Correspondence: Ran Xu
| |
Collapse
|
3
|
Gross Hematuria in an Adolescent Secondary to a Rare Bladder Tumor: A Case Report and Review of Inflammatory Myofibroblastic Tumors of the Urinary Bladder. Urology 2022; 165:e39-e45. [DOI: 10.1016/j.urology.2022.01.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 01/13/2022] [Accepted: 01/23/2022] [Indexed: 11/19/2022]
|
4
|
Kim MS, Lim SC. A Rare Case of Inflammatory Myofibroblastic Tumor of the Prostate and Review of the Literature. IN VIVO (ATHENS, GREECE) 2020. [PMID: 32606180 DOI: 10.21873/invivo.12005.] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Inflammatory myofibroblastic tumor (IMT) is a rare type of soft-tissue neoplasm. IMT of the urinary tract is more common in the bladder and kidneys. Prostatic IMT is extremely rare. CASE REPORT We present a rare case of IMT of the prostate and a literature review on this condition. The patient was a 72-year-old man who presented with urinary symptoms. Transrectal needle biopsy of the prostate revealed prostatic adenocarcinoma with nodular hyperplasia. Radical prostatectomy revealed IMT without residual adenocarcinoma. On immunohistochemical examination, the tumor cells showed positive immunoreactivity for α-smooth muscle actin, CD10, CD34, and desmin but negative immunoreactivities for anaplastic lymphoma kinase (ALK), receptor tyrosine kinase (c-KIT), and S-100 protein. The patient underwent regular follow-up examination. No recurrence was observed 4 months after the diagnosis. CONCLUSION This was a case of IMT arising in the prostate. Pathologists should be aware of such an entity whenever they see spindle-cell lesions in the transrectal needle biopsy of the prostate.
Collapse
Affiliation(s)
- Min Seok Kim
- Department of Urology, College of Medicine, Chosun University, Gwangju, Republic of Korea
| | - Sung-Chul Lim
- Department of Pathology, College of Medicine, Chosun University, Gwangju, Republic of Korea
| |
Collapse
|
5
|
Kim MS, Lim SC. A Rare Case of Inflammatory Myofibroblastic Tumor of the Prostate and Review of the Literature. In Vivo 2020; 34:2043-2048. [PMID: 32606180 PMCID: PMC7439877 DOI: 10.21873/invivo.12005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 04/02/2020] [Accepted: 04/08/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND Inflammatory myofibroblastic tumor (IMT) is a rare type of soft-tissue neoplasm. IMT of the urinary tract is more common in the bladder and kidneys. Prostatic IMT is extremely rare. CASE REPORT We present a rare case of IMT of the prostate and a literature review on this condition. The patient was a 72-year-old man who presented with urinary symptoms. Transrectal needle biopsy of the prostate revealed prostatic adenocarcinoma with nodular hyperplasia. Radical prostatectomy revealed IMT without residual adenocarcinoma. On immunohistochemical examination, the tumor cells showed positive immunoreactivity for α-smooth muscle actin, CD10, CD34, and desmin but negative immunoreactivities for anaplastic lymphoma kinase (ALK), receptor tyrosine kinase (c-KIT), and S-100 protein. The patient underwent regular follow-up examination. No recurrence was observed 4 months after the diagnosis. CONCLUSION This was a case of IMT arising in the prostate. Pathologists should be aware of such an entity whenever they see spindle-cell lesions in the transrectal needle biopsy of the prostate.
Collapse
Affiliation(s)
- Min Seok Kim
- Department of Urology, College of Medicine, Chosun University, Gwangju, Republic of Korea
| | - Sung-Chul Lim
- Department of Pathology, College of Medicine, Chosun University, Gwangju, Republic of Korea
| |
Collapse
|
6
|
Zeng J, He RQ, Mo WG, Peng ZG, Ma J, Zhong JC, Mo CH, Qin MJ, Hu XH. Inflammatory myofibroblastic tumor of the prostate after transurethral resection of the prostate with negative expression of anaplastic lymphoma kinase: a case report. SAO PAULO MED J 2018; 136:484-487. [PMID: 29898011 PMCID: PMC9907760 DOI: 10.1590/1516-3180.2017.0079070417] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 04/07/2017] [Indexed: 12/16/2022] Open
Abstract
CONTEXT Inflammatory myofibroblastic tumors are a rare type of soft-tissue tumor. Inflammatory myofibroblastic tumors are characterized by rearrangements involving the anaplastic lymphoma kinase gene locus on 2p23. CASE REPORT We report the case of a 67-year-old Chinese male who presented with dysuria and fever. Magnetic resonance imaging showed an irregular prostatic mass with an isointense signal and obscure boundary. Histopathological evaluation showed that the mass consisted mainly of spindle-shaped cells. Immunohistochemical evaluation showed that the tumor cells were negative for anaplastic lymphoma kinase. CONCLUSIONS Inflammatory myofibroblastic prostate tumors are rare lesions with unclear etiology. The pathological diagnosis is very important.
Collapse
Affiliation(s)
- Jie Zeng
- MD, MSc. Postgraduate Student, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Rong-Quan He
- MD. Postgraduate Student, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Wei-Guang Mo
- MSc. Technician, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Zhi-Gang Peng
- MD, MSc. Professor, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Jie Ma
- MD, MSc. Professor, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Jin-Cai Zhong
- MD, MSc. Professor, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Chao-Hua Mo
- MD, MSc. Attending Physician and Postgraduate Student, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Mei-Jiao Qin
- MD, MSc. Postgraduate Student, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Xiao-Hua Hu
- MD, MSc. Professor, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| |
Collapse
|
7
|
Yuan C, Ma MJ, Parker JV, Mekhail TM. Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report. AMERICAN JOURNAL OF CASE REPORTS 2017; 18:799-804. [PMID: 28713152 PMCID: PMC5528006 DOI: 10.12659/ajcr.903698] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Patient: Female, 18 Final Diagnosis: Inflammatory myofibroblastic sarcoma Symptoms: Headache Medication: — Clinical Procedure: Craniotomy • lobectomy Specialty: Oncology
Collapse
Affiliation(s)
- Cai Yuan
- Department of Internal Medicine, Florida Hospital Internal Medicine Residency, Orlando, FL, USA
| | - Muchou J Ma
- Department of Pathology, Florida Hospital, Orlando, FL, USA
| | - John V Parker
- Department of Obstetrics and Gynecology, Florida Hospital, Orlando, FL, USA
| | | |
Collapse
|
8
|
Koukoura O, Alevra Z, Pavlakis K, Pistofidis G. Laparoscopic excision of an inflammatory myofibroblastic tumour of the bladder disguised as deep infiltrating endometriosis. BMJ Case Rep 2017; 2017:bcr-2017-220189. [PMID: 28710194 DOI: 10.1136/bcr-2017-220189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Inflammatory myofibroblastic tumour (IMT) of the bladder is a rare tumour of indeterminate malignant potential with myofibroblastic differentiation, with a generally benign but rarely aggressive behaviour. Vesical IMT is usually treated by transurethral resection or partial cystectomy. Herein we describe a case of a woman who underwent laparoscopic excision of an IMT of the bladder, initially diagnosed as deep infiltrating endometriosis.
Collapse
Affiliation(s)
- Ourania Koukoura
- Department of Obstetrics and Gynaecology, University Hospital of Larissa, Larissa, Greece
| | - Zoi Alevra
- Department of Obstetrics and Gynaecology, University Hospital of Larissa, Larissa, Greece
| | - Kitty Pavlakis
- Department of Pathology, Medical School, The National and Kapodistrian University of Athens, Athens, Greece
| | - George Pistofidis
- Department of Gynecologic Endoscopy, Lefkos Stavros Hospital, Athens, Greece
| |
Collapse
|
9
|
Mansour-Ghanaei F, Gharibpoor A, Joukar F, Mavaddati S, Askari K, Askari SA, Gharibpoor F. Inflammatory Myofibroblastic Tumors in a Case with Hypogastric Discomfort. AMERICAN JOURNAL OF CASE REPORTS 2017; 18:217-221. [PMID: 28250406 PMCID: PMC5344281 DOI: 10.12659/ajcr.901813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Patient: Male, 68 Final Diagnosis: Inflammatory myofibroblastic tumor Symptoms: 2–3 kg weight loss • Helicobacter pylori positive which were eradicated after treatment course • hypogastric region discomfort • no association between the pain, defecation and eating • no history of HIV, diabetes, smoking and alcohol consumption was recorded • no symptoms of nausea, vomiting, fever and shaking chills • normal vital signs • tenderness in the right lower quadrant of the abdomen with no rebound state was noted Medication: — Clinical Procedure: Lab examinationt-imaging-colonoscopy-surgery Specialty: Gastroenterology and Hepatology
Collapse
Affiliation(s)
- Fariborz Mansour-Ghanaei
- Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
| | - Alireza Gharibpoor
- Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
| | - Farahnaz Joukar
- Caspian Digestive Diseases Research Center (CDDRC), Guilan University of Medical Sciences, Rasht, Iran
| | - Sara Mavaddati
- Caspian Digestive Diseases Research Center (CDDRC), Guilan University of Medical Sciences, Rasht, Iran
| | - Kourosh Askari
- Department of Pathology, Guilan University of Medical Sciences, Rasht, Iran
| | - Seyed Ali Askari
- Caspian Digestive Diseases Research Center (CDDRC), Guilan University of Medical Sciences, Rasht, Iran
| | - Faeze Gharibpoor
- Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
| |
Collapse
|
10
|
GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. Sci Rep 2015; 5:14000. [PMID: 26354850 PMCID: PMC4564850 DOI: 10.1038/srep14000] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Accepted: 07/31/2015] [Indexed: 02/07/2023] Open
Abstract
SNPs may restrict cell detoxification activity and be a potential risk factor for cancer chemosensitivity. We evaluated the predictive value of these polymorphisms on the sensitivity of bladder cancer patients to epirubicin and mitomycin chemotherapy instillation as well as their toxicities. SNPs were analyzed by TaqMan genotyping assays in 130 patients treated with epirubicin and 114 patients treated with mitomycin. Recurrence-free survival (RFS) was estimated by the Kaplan-Meier method, and hazard ratios (HRs) and 95% confidence intervals (CIs) of the HRs were derived from multivariate Cox proportional hazard models. GSTP1 rs1695 and GSTO1 rs4925 were also associated with RFS in the epirubicin group. Patients carrying the GSTP1 AG+GG and GSTO1 AC+AA genotypes had an unfavorable RFS. Patients with the GSTP1 AA and GSTO1 CC genotypes had a reduced risk of recurrence after the instillation of epirubicin. In addition, patients with the GSTP1 rs1695 AA genotype had an increased risk of irritative voiding symptoms; while patients with the GSTO1 rs4925 CC genotype had a decreased risk of hematuria. Our results suggest that GSTP1 and GSTO1 polymorphisms are associated with epirubicin treatment outcomes as well as with epirubicin-related toxicity.
Collapse
|
11
|
Li W, Gu M. SULT1A1 Arg213His polymorphism is associated with bladder cancer risk: a meta-analysis. Med Sci Monit 2014; 20:1590-5. [PMID: 25194687 PMCID: PMC4166222 DOI: 10.12659/msm.890822] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background The evidence of an association between the Sulfotransferase 1A1 (SULT1A1) Arg213His polymorphism (rs9282861) and bladder cancer risk is still conflicting. We conducted a meta-analysis to assess the association between this polymorphism and bladder cancer risk. Material/Methods PubMed, EMBASE, HuGE Navigator, and Web of Science databases were searched for correlative articles. The risk (odds ratio, OR) was used to estimate the association between SULT1A1 Arg213His polymorphism and bladder cancer risk. All of the studies used either fixed-effects or random-effects models. For assessing the credibility of an association, we applied the Venice criteria. Results Seven published case-control studies with 1688 cases and 2842 controls were included in this meta-analysis. There were 5 studies of Caucasians and 2 studies of Asians. Four studies reported data on smoking behavior. The percentage of Arg/Arg was higher in Asians and non-smokers than that in Caucasians and smokers, respectively. A significant association of this polymorphism with bladder cancer was found (OR=1.45, 95% CI 1.18–1.78, P=0.0004). In the subgroup analysis by ethnicity, a significant association was found among Caucasians (OR=1.43, 95% CI 1.16–1.77, P=0.0008) but not among Asians (OR=1.89, 95% CI 0.68–5.26, P=0.22). In the subgroup analysis by smoking behavior, increased bladder cancer risk was found in the smokers (OR=1.39, 95% CI 1.01–1.91, P=0.04) and non-smokers (OR=1.74, 95% CI 1.24–2.43, P=0.001). Conclusions In conclusion, this meta-analysis indicated that SULT1A1 Arg213His polymorphism is associated with bladder cancer risk.
Collapse
Affiliation(s)
- Wencheng Li
- Department of Urology, Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China (mainland)
| | - Min Gu
- Department of Urology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China (mainland)
| |
Collapse
|